The Bacillus Calmette-Guérin (BCG) is a live attenuated tuberculosis vaccine that has the
ability to induce non-specific cross-protection against pathogens that might be unrelated to …

A number of new tuberculosis (TB) vaccines have been or are entering clinical trials, which
include genetically modified mycobacteria, mycobacterial antigens delivered by viral …

Abstract T helper type 1 (Th1) lymphocytes secrete secrete interleukin (IL)-2, interferon-γ,
and lymphotoxin-α and stimulate type 1 immunity, which is characterized by intense …

Aim: to study the efficacy of BCG vaccinations, once a month for 3 consecutive months, in
elderly on the prevention of acute upper respiratory tract infection (AURTI), interferon …

Data obtained in animals indicate that neonatal immune responses are biased toward Th2.
This could reduce the efficacy of vaccines against viral and mycobacterial diseases. The …

Background The efficacy of BCG vaccines against pulmonary tuberculosis varies between
populations, showing no protection in Malawi but 50–80% protection in the UK. To …

BCG turns 100 this year and while it might not be the perfect vaccine, it has certainly
contributed significantly towards eradication and prevention of spread of tuberculosis (TB) …

Human T cell responses to ESAT-6 and eight synthetic overlapping peptides were
investigated in tuberculosis (TB) patients and control subjects from regions of high and low …

ABSTRACT In Great Britain an independent scientific review for the government has
concluded that the development of a cattle vaccine against Mycobacterium bovis infection …

Abstract Interferon-α (IFN-α) has proven to be a clinically effective antiviral and
antineoplastic therapeutic drug for more than 16 years. During this time, evidence from in …